Floatz logo

Therapeutic Asset Ratings

374 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
AssetSponsorPhaseRating
aaa802
Prostate Cancer
Novartis PharmaceuticalsP1/2CC (40)
Gallium-68 Labelled Fap-2286
Neoplasm
Novartis PharmaceuticalsP1/2CC (40)
Opnurasib
Colorectal Cancer
Novartis PharmaceuticalsP1/2CC (40)
Siremadlin
Acute Myeloid Leukemia
Novartis PharmaceuticalsP1/2CC (40)
Tulmimetostat
Cancer
Novartis PharmaceuticalsP1/2CC (40)
177lu-ff58
Gastroesophageal Adenocarcinoma
Novartis PharmaceuticalsP1C (39)
68ga-dfc413
Colorectal Cancer
Novartis PharmaceuticalsP1C (39)
68ga-dfc413
Non-Small Cell Lung Carcinoma
Novartis PharmaceuticalsP1C (39)
68ga-dfc413
Triple-Negative Breast Carcinoma
Novartis PharmaceuticalsP1C (39)
[68ga]ga-dwj155
Urinary Bladder Carcinoma
Novartis PharmaceuticalsP1C (39)
iag933
Mesothelioma
Novartis PharmaceuticalsP1C (39)
inr731
Castration-Resistant Prostate Carcinoma
Novartis PharmaceuticalsP1C (39)
kfa115
Anal Carcinoma
Novartis PharmaceuticalsP1C (39)
kfa115
Mesothelioma
Novartis PharmaceuticalsP1C (39)
nio752
Cognitive Disorder
Novartis PharmaceuticalsP1C (39)
qeq278
Esophageal Squamous Cell Carcinoma
Novartis PharmaceuticalsP1C (39)
Spartalizumab
Nasopharyngeal Carcinoma
Novartis PharmaceuticalsP1C (39)
68ga-ff58
Brain Neoplasm
Novartis PharmaceuticalsEarly P1C (39)
ltt462
Melanoma
Novartis PharmaceuticalsP2C (37)
177lu-dfc413
Pancreatic Ductal Adenocarcinoma
Novartis PharmaceuticalsP1C (37)
177lu-dfc413
Triple-Negative Breast Carcinoma
Novartis PharmaceuticalsP1C (37)
177lu-ff58
Pancreatic Ductal Adenocarcinoma
Novartis PharmaceuticalsP1C (37)
[177lu]lu-evs459
Lung Cancer
Novartis PharmaceuticalsP1C (37)
[177lu]lu-nns309
Pancreatic Ductal Adenocarcinoma
Novartis PharmaceuticalsP1C (37)
[177lu]lu-nns309
Triple-Negative Breast Carcinoma
Novartis PharmaceuticalsP1C (37)
Showing 301 to 325 of 374 assets
PreviousPage 13 of 15Next